Lunai Bioworks Inc.
LNAINasdaqCIK 1527728HealthcareFiscal year ends Jun 30
Latest reported revenue, Q4 FY2026$31.1kRevenue, Q4 FY2026, three months to 2026-06-30$31.1k. XBRL concept
us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Jun 30, 2026, from the 10-K filed Oct 13, 2026.Latest quarter: Q4 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenue$31.1kRevenue, Q4 FY2026, three months to 2026-06-30$31.1k. XBRL concept
us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figureNo year-earlier figure to compare - Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
- Operating margin−6888.6%Operating margin, Q4 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$2.1m. XBRL concept
us-gaap:OperatingIncomeLoss. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Revenue: $31.1k. XBRL conceptus-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figureNo year-earlier figure to compare - Net margin−6475.7%Net margin, Q4 FY2026, three months to 2026-06-30. net income / revenueNet income: −$2.0m. XBRL concept
us-gaap:NetIncomeLoss. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Revenue: $31.1k. XBRL conceptus-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figureNo year-earlier figure to compare - Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
- Free cash flow−$1.8mFree cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.8m. XBRL concept
us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL conceptus-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figureNo year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q1 FY20252024-09-30 | Q2 FY20252024-12-31 | Q3 FY20252025-03-31 | Q4 FY20252025-06-30 | Q1 FY20262025-09-30 | Q2 FY20262025-12-31 | Q3 FY20262026-03-31 | Q4 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $k | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | 20.9Revenue, Q3 FY2026, three months to 2026-03-31$20.9k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Report this figure | 31.1Revenue, Q4 FY2026, three months to 2026-06-30$31.1k. XBRL concept us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figure | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | 100.0%Gross margin, Q3 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $20.9k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Revenue: $20.9k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Report this figure | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (7054.1%)Operating margin, Q3 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$1.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Revenue: $20.9k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Report this figure | (6888.6%)Operating margin, Q4 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Revenue: $31.1k. XBRL concept us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figure | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (12278.6%)Net margin, Q3 FY2026, three months to 2026-03-31. net income / revenueNet income: −$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Revenue: $20.9k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Report this figure | (6475.7%)Net margin, Q4 FY2026, three months to 2026-06-30. net income / revenueNet income: −$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Revenue: $31.1k. XBRL concept us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figure | |
| Diluted EPS | $ per share | (2.76)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$2.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001731122-25-001544.Report this figure | (0.45)Diluted EPS, Q2 FY2025, three months to 2024-12-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001731122-26-000253.Report this figure | 0.00Diluted EPS, Q3 FY2025, three months to 2025-03-31$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Report this figure | not reported (Diluted EPS not reported) | 0.13Diluted EPS, Q1 FY2026, three months to 2025-09-30$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001731122-25-001544.Report this figure | (0.08)Diluted EPS, Q2 FY2026, three months to 2025-12-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-17, accession 0001731122-26-000253.Report this figure | (0.10)Diluted EPS, Q3 FY2026, three months to 2026-03-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001731122-26-000749.Report this figure | not reported (Diluted EPS not reported) | |
| Free cash flow | $k | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | (1,027)Free cash flow, Q3 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001731122-26-000749. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-15, accession 0001731122-26-000749. Derived: 9-month figure less the 6-month figure.Report this figure | (1,841)Free cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-10-13, accession 0001731122-26-001339. Derived: 12-month figure less the 9-month figure.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20222022-06-30 | FY20232023-06-30 | FY20242024-06-30 | FY20252025-06-30 | FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | 0.1Revenue, FY2026, twelve months to 2026-06-30$52.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339.Report this figure | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (16729.4%)Operating margin, FY2026, twelve months to 2026-06-30. operating income / revenueOperating income: −$8.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-10-13, accession 0001731122-26-001339.Revenue: $52.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339.Report this figure | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (6852.0%)Net margin, FY2026, twelve months to 2026-06-30. net income / revenueNet income: −$3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-10-13, accession 0001731122-26-001339.Revenue: $52.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-10-13, accession 0001731122-26-001339.Report this figure | |
| Diluted EPS | $ per share | (2.16)Diluted EPS, FY2022, twelve months to 2022-06-30−$2.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-10-02, accession 0001731122-23-001770.Report this figure | (0.71)Diluted EPS, FY2023, twelve months to 2023-06-30−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K/A filed 2025-02-19, accession 0001731122-25-000252.Report this figure | (0.91)Diluted EPS, FY2024, twelve months to 2024-06-30−$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-09-29, accession 0001731122-25-001316.Report this figure | (86.27)Diluted EPS, FY2025, twelve months to 2025-06-30−$86.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-10-13, accession 0001731122-26-001339.Report this figure | (1.06)Diluted EPS, FY2026, twelve months to 2026-06-30−$1.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-10-13, accession 0001731122-26-001339.Report this figure | |
| Free cash flow | $m | (15.7)Free cash flow, FY2022, twelve months to 2022-06-30. operating cash flow − capital expenditureOperating cash flow: −$15.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-10-02, accession 0001731122-23-001770.Capital expenditure: $5.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-10-02, accession 0001731122-23-001770.Report this figure | (11.8)Free cash flow, FY2023, twelve months to 2023-06-30. operating cash flow − capital expenditureOperating cash flow: −$11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K/A filed 2025-02-19, accession 0001731122-25-000252.Capital expenditure: $29.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2025-02-19, accession 0001731122-25-000252.Report this figure | (11.0)Free cash flow, FY2024, twelve months to 2024-06-30. operating cash flow − capital expenditureOperating cash flow: −$11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-09-29, accession 0001731122-25-001316.Capital expenditure: $70.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-09-29, accession 0001731122-25-001316.Report this figure | not reported (Capital expenditure not reported) | (5.3)Free cash flow, FY2026, twelve months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-10-13, accession 0001731122-26-001339.Capital expenditure: $1.2k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-10-13, accession 0001731122-26-001339.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Ground Swell Capital, LLC | 2026-06-30 | $174.0k | 53,211 | New+53,211 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-06-30 | $79.0k | 24,156 | New+24,156 | |
| JANE STREET GROUP, LLC | 2026-06-30 | $77.4k | 23,683 | New+23,683 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $52.6k | 16,081 | New+16,081 | |
| BlackRock, Inc. | 2026-06-30 | $52.0k | 15,906 | New+15,906 | |
| VANGUARD FIDUCIARY TRUST CO | 2026-06-30 | $28.3k | 8,642 | New+8,642 | |
| ROYAL BANK OF CANADA | 2026-06-30 | $5.0k | 1,687 | New+1,687 | |
| Tower Research Capital LLC (TRC) | 2026-06-30 | $4.6k | 1,405 | New+1,405 | |
| GROUP ONE TRADING LLC | 2026-06-30 | $1.8k | 544 | New+544 | |
| MORGAN STANLEY | 2026-06-30 | $1.1k | 326 | New+326 |
Recent filings
All 598 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2321:38 ET | 8-K | 3.01 Delisting notice; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001362 |
| 2026-10-1521:13 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001214659-26-012970 |
| 2026-10-1316:55 ET | 10-K | Annual reportPeriod 2026-06-30 | 0001731122-26-001339 |
| 2026-10-0914:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001333 |
| 2026-06-1716:32 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-000871 |
| 2026-06-1616:00 ET | 8-K | 8.01 Other events | 0001731122-26-000865 |
| 2026-05-2009:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-000759 |
| 2026-05-1516:46 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001731122-26-000749 |
| 2026-05-1316:45 ET | 8-K | 5.07 Shareholder vote results | 0001731122-26-000718 |
| 2026-05-1117:30 ET | 8-K/A | 3.01 Delisting notice | 0001731122-26-000705 |
Latest annual report
Form 10-K for the fiscal year ended Jun 30, 2026Filed Oct 13, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1527728
- Tickers
- LNAI
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Jun 30
- Incorporated in
- DE
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- RENOVARO INC. (to 2025-08-26); RENOVARO BIOSCIENCES INC. (to 2024-02-07); Enochian Biosciences Inc (to 2023-08-01); DanDrit Biotech USA, Inc. (to 2018-02-23); Putnam Hills Corp. (to 2014-02-11)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 06:04 ET. Listed shows no prices and gives no investment advice.